Benzinga··Lekha GuptaProfusa Plunges 40% on $30M BioInsights Acquisition Despite Strategic Rationale
Profusa shares crashed 40% Tuesday after announcing $30M all-equity deal to acquire BioInsights' multi-omics diagnostics platform, expanding into molecular cancer detection.
PFSAstock declineacquisition